Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00406107 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
A Phase 4 study of Branch Retinal Vein Occlusion, sponsored by Palmetto Retina Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT00406107: Completed Phase 4 study of Branch Retinal Vein Occlusion, sponsored by Palmetto Retina Center.
NCT00406107 is a Phase 4 study of Branch Retinal Vein Occlusion that has completed, run by Palmetto Retina Center. The registered enrollment target is 20 participants, below the 2,065-participant average among 3 other Branch Retinal Vein Occlusion trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00406107, a Phase 4 study of Branch Retinal Vein Occlusion, has completed, sponsored by Palmetto Retina Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of intravitreal injections of Macugen every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). We hypothesize that macular edema secondary to BRVO is mediated by VEGF 165 and that chronic suppression of VEGF 165 will successfully treat BRVO related macular edema.
Conditions Studied
Interventions
- DRUG pegaptanib sodium (Macugen)
Study Locations (3)
California
- Jules Stein Eye Institute - Los Angeles
Maryland
- Cumberland Valley Retina Center - Hagerstown
South Carolina
- Palmetto Retina Center - West Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
What the finished NCT00406107 record still lists
NCT00406107 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 2,065-participant average among 3 other Branch Retinal Vein Occlusion trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Branch Retinal Vein Occlusion appearing as the primary indexed condition, and to 1 intervention - of which pegaptanib sodium (Macugen) is the first listed.
NCT00406107 reports a single indexed study location in California, Maryland, South Carolina.
Frequently Asked Questions
What is clinical trial NCT00406107 about?
NCT00406107 is a clinical study titled "Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion". The purpose of this study is to evaluate the effect of intravitreal injections of Macugen every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). We hypothesize that macular edema secondary to BRVO is mediated by VEGF 165 and that chronic suppression of VE...
What is the current status of trial NCT00406107?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2006-01. Estimated completion is 2008-04.
What conditions does trial NCT00406107 study?
This clinical trial studies the following conditions: Branch Retinal Vein Occlusion.
What interventions are being tested in trial NCT00406107?
The interventions under investigation include: pegaptanib sodium (Macugen) (DRUG).
Who is sponsoring clinical trial NCT00406107?
This trial is sponsored by Palmetto Retina Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00406107 being conducted?
This trial has 3 study locations across California, Maryland, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Branch Retinal Vein Occlusion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
ACTIVE NOT RECRUITING
-
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
COMPLETED · Phase 2
-
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia